KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBIT Margin (2016 - 2025)

Historic EBIT Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 17912.5%.

  • CRISPR Therapeutics AG's EBIT Margin fell 177315400.0% to 17912.5% in Q4 2025 from the same period last year, while for Dec 2025 it was 18933.65%, marking a year-over-year decrease of 176832700.0%. This contributed to the annual value of 18933.65% for FY2025, which is 176832700.0% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported EBIT Margin of 17912.5% as of Q4 2025, which was down 177315400.0% from 14854.78% recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EBIT Margin ranged from a high of 84.67% in Q2 2021 and a low of 2192350.0% during Q4 2022
  • In the last 5 years, CRISPR Therapeutics AG's EBIT Margin had a median value of 17912.5% in 2025 and averaged 142655.16%.
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBIT Margin plummeted by 2000000000bps in 2022 and then soared by 2000000000bps in 2023.
  • CRISPR Therapeutics AG's EBIT Margin (Quarter) stood at 1129.53% in 2021, then crashed by -193994bps to 2192350.0% in 2022, then skyrocketed by 100bps to 34.58% in 2023, then tumbled by -623bps to 180.96% in 2024, then crashed by -9798bps to 17912.5% in 2025.
  • Its EBIT Margin was 17912.5% in Q4 2025, compared to 14854.78% in Q3 2025 and 25708.97% in Q2 2025.